Tumour Microenvironment in Therapy of Metastatic Cancer
Journal Title: Diseases & Research - Year 2023, Vol 3, Issue 2
Abstract
GLOBOCAN 2020 has reported that the global cancer burden is 19.3 million cases, with 10 million deaths[1]. The overall survival (OS) after treatment with innovative cancer therapies has not changed for most metastatic cancer patients, and more in-depth study is needed. Several studies have suggested that understanding the cellular and molecular mechanisms underlying metastatic processes can be used as a novel strategy to disrupt cancer cell pathways and contribute to the development of effective and safe therapies against metastatic cancer. Recent studies have shown that the tumour microenvironment (TME) is responsible for reprogramming tumour initiation, progression, invasion, and metastasis. Thus, TME probably hinders positive responses to innovative therapies. Therefore, clinicians must consider targeting major cell components associated with TME instead of only using presently available genomic profiles of tumours for effective treatment of metastatic cancer patients. Various investigators have already identified specific cell types from TME that are involved in the progression and resistance of cancer cells[2]. These include circulating tumour cells (CTCs), cancer-associated fibroblasts (CAFs), cancer stem cells (CSCs), immune cells, endothelial cells, etc., from highly metastatic cancer patients. The development of this support niche is critical for persistent uncontrolled growth of cancer at the metastatic stage. This special issue on “Tumour Microenvironment in Therapy of Metastatic Cancer” describes various cell types and components involved in tumour growth, invasion and metastasis, and also addresses various strategies that can be implemented to target these resistant cancer cells for effective cure of metastatic cancer in the near future.
Authors and Affiliations
Pravin D. Potdar
Keywords
Related Articles
- EP ID EP740188
- DOI 10.54457/DR.202302008
- Views 60
- Downloads 1
Clinical Applications of Recombinant Human Granulocyte Colony-Stimulating Factor in Reproductive Medicine: Expert Consensus
Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is primarily indicated for neutropenia caused by various etiologies in clinical practice. Recently, it has been shown to have some therapeutic effects and...
Hepatic Paragonimiasis: A Case Report and Literature Review
Paragonimiasis is a parasitic disease caused by paragnonimus, which primarily caused infection in the lung, and ectopic infection was less common. Ectopic paragonimiasis are more likely to be misdiagnosed as malignancy o...
Exploring Oncogenic Factors Influence on Multiple Myeloma Progression and Patient Survival
Backgrounds Multiple myeloma (MM), one of the most prevalent hematological malignancies, is characterized by the proliferation of plasma cells within bone marrow and concurrent development of osteolytic lesions. The pers...
Significance of Liquid Biopsy Containing Circulating Tumor DNA (ctDNA) Analysis for Evaluation and Management of Metastatic Cancer
According to the GLOBOCAN 2020 data from WHO, nearly 10 million deaths took place due to cancer thus, cancer became a leading cause of death all over the world. The most common cancer are breast cancer, lung cancer, colo...
Is Preoperative Radiotherapy Necessary for Resectable Locally Advanced Squamous Cell Esophageal Carcinoma?
Based on the guidelines for esophageal and esophagogastric junction cancers, the standard of care for resectable locally advanced (cT2, N0 [high-risk lesions: lymphovascular invasion, ≥3 cm, poorly differentiated]; cT1b-...